Smith & Nephew plc (SN) Given “Neutral” Rating at JPMorgan Chase & Co.

smith-038-nephew-plc-sn-given-8220neutral8221-rating-at-jpmorgan-chase-038-co.gif

Smith & Nephew plc (LON:SN)‘s stock had its “neutral” rating restated by stock analysts at JPMorgan Chase & Co. in a research report issued on Wednesday. They presently have a GBX 1,199 ($15.97) target price on the stock. JPMorgan Chase & Co.’s price target indicates a potential downside of 1.48% from the stock’s previous close.
Several other equities analysts also recently issued reports on the company. Goldman Sachs Group Inc. reissued a “buy” rating on shares of Smith & Nephew plc in a research report on Tuesday. Jefferies Group reissued a “buy” rating and issued a GBX 1,420 ($18.91) target price on shares of Smith & Nephew plc in a research report on Friday, August 12th. Barclays PLC downgraded Smith & Nephew plc to an “equal weight” rating and upped their target price for the company from GBX 1,230 ($16.38) to GBX 1,240 ($16.52) in a research report on Wednesday, August 10th. Beaufort Securities reissued a “hold” rating on shares of Smith & Nephew plc in a research report on Tuesday, August 9th. Finally, Deutsche Bank AG reaffirmed a “hold” rating and set a GBX 1,150 ($15.32) price target on shares of Smith & Nephew plc in a research report on Tuesday, August 2nd. Nine equities research analysts have rated the stock with a hold rating and five have given a buy rating to the company. The company currently has a consensus rating of “Hold” and an average target price of GBX 1,294.92 ($17.25).
Shares of Smith & Nephew plc (LON:SN) opened at 1217.00 on Wednesday. The stock has a 50 day moving average price of GBX 1,250.42 and a 200 day moving average price of GBX 1,196.20. The company’s market capitalization is GBX 10.88 billion. Smith & Nephew plc has a one year low of GBX 1,006.20 and a one year high of GBX 1,324.00.

This story is the sole property of American Banking News and it was originally published by American Banking News. If you are reading this story on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. The original version of this article is available at http://www.americanbankingnews.com/2016/09/14/smith-nephew-plc-sn-given-neutral-rating-at-jpmorgan-chase-co.html

In related news, insider Bottomley ,Virginia purchased 238 shares of the firm’s stock in a transaction that occurred on Monday, August 15th. The shares were purchased at an average cost of GBX 1,290 ($17.18) per share, with a total value of £3,070.20 ($4,089.24).
Smith & Nephew plc Company Profile
Smith & Nephew plc is a medical technology company. The Company is engaged in developing, manufacturing, marketing and selling medical devices and services. The Company offers various product franchises, which include Knee implants, Hip implants, Sports Medicine Joint Repair, Arthroscopy Enabling Technologies, Trauma and Extremities, Other Surgical Businesses, Advanced Wound Care, Advanced Wound Devices and Advanced Wound Bioactives.

Receive News & Ratings for Smith & Nephew plc Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Smith & Nephew plc and related companies with MarketBeat.com’s FREE daily email newsletter.

Be the first to comment on "Smith & Nephew plc (SN) Given “Neutral” Rating at JPMorgan Chase & Co."

Leave a comment

Your email address will not be published.

*